Novo Nordisk The stock has lost 50% of its value in the last year due to a combination of factors: In Q1 2025, U.S
Clinical trials reported no serious adverse events, with mostly mild to moderate side effects such as headache, dry mouth, and insomnia
The burden of Parkinsons disease: a worldwide perspective
The NOS evaluates studies based on three criteria: (1) selection of study groups (representativeness, ascertainment of exposure, and demonstration that the outcome was not present at baseline), (2) comparability of groups (control for confounding factors), and (3) assessment of outcome (adequacy of follow-up and blinding of outcome assessment)
At Newport Beach UC, patients receive more than medicationthey gain a partner committed to guiding every step of the journey
You can watch the full documentary, A Year For a Life , here